"None of the listed chemical companies has the same business as Rossari. We believe Rossari will command a premium over most of its chemical peers as it is net debt-free as well as it has better asset turnover, working capital days, RoE and RoCE better than most of its peers. Only 10 percent of sales are dependent on imported raw material, of which less than 5 percent comes from China. As we are positive on the future outlook for the industry as well as the company, we would recommend subscribing to the issue," Angel Broking said. … [Read more...] about Analysts say subscribe to Rossari Biotech IPO despite high valuation, here is why
After a lull in the IPO market since the SBI Card issue, Rossari Biotech is kick-startingthe IPO season with its Rs 496 crore fresh issue and offer-for- sale (OFS). The company already garnered Rs 149 crore through its anchor book on July 10 and has been subscribed 8 percent so far on July 13, day one of bidding. … [Read more...] about Ideas for Profit | Rossari Biotech IPO opens for subscription today; should you subscribe?